Norge -
norsk -
Statens legemiddelverk
rehydrex med glucos
fresenius kabi norge as - halden - glukosemonohydrat / natriumacetattrihydrat / natriumklorid - infusjonsvæske, oppløsning - 25 mg/ ml
Norge -
norsk -
Statens legemiddelverk
rehydrex med glucos
fresenius kabi norge as - halden - glukosemonohydrat / natriumacetattrihydrat / natriumklorid - infusjonsvæske, oppløsning - 50 mg/ ml
Norge -
norsk -
Statens legemiddelverk
ringer-acetat fresenius kabi
fresenius kabi norge as - halden - natriumklorid / natriumacetattrihydrat / kaliumklorid / kalsiumkloriddihydrat / magnesiumkloridheksahydrat - infusjonsvæske, oppløsning - 5.9 g/ l / 4.1 g/ l / 0.3 g/ l / 0.295 g/ l / 0.2 g/ l
Norge -
norsk -
Statens legemiddelverk
ursochol 250 mg
orifarm generics a/s - ursodeoksykolsyre - kapsel, hard - 250 mg
Norge -
norsk -
Statens legemiddelverk
ursofalk 500 mg
dr. falk pharma gmbh - ursodeoksykolsyre - tablett, filmdrasjert - 500 mg
Norge -
norsk -
Statens legemiddelverk
ursofalk 250 mg
dr. falk pharma gmbh - ursodeoksykolsyre - kapsel, hard - 250 mg
Norge -
norsk -
Statens legemiddelverk
ursofalk 50 mg/ ml
dr. falk pharma gmbh - ursodeoksykolsyre - mikstur, suspensjon med sitronsmak - 50 mg/ ml
Norge -
norsk -
Statens legemiddelverk
ursodeoxycholic acid orion 250 mg
orion corporation - espoo - ursodeoksykolsyre - kapsel, hard - 250 mg
Norge -
norsk -
Statens legemiddelverk
empressin 20 ie/ ml
orpha-devel handels und vertriebs gmbh - argipressinmonoacetat - konsentrat til infusjonsvæske, oppløsning - 20 ie/ ml
Den europeiske union -
norsk -
EMA (European Medicines Agency)
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiske midler - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.